ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up
Sixty-seven percent of GA101-treated patients experience a serious side effect, including 34% reporting significant drops in white blood cell counts known as neutropenia. By comparison, the rate of serious adverse events associated with chemotherapy was 41 percent, including 15% occurrence of neutropenia.
These are the data Roche filed with FDA seeking GA101's approval but investors are more interested in how GA101 stacks up against Rituxan. The second stage of the phase III study is not ready for a final analysis, but preliminary data released Wednesday shows GA101 might be a better drug.
CLL patients treated with Rituxan reported a median PFS of 15.7 months, which is numerically inferior to the 23-month median PFS for GA101. The Rituxan data will change, however, as the study matures. Roche expects to have more definitive results from the second stage of the study later this year.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV